Current position

Ray Dalio’s Dexcom Inc (DXCM) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2020Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares633.05KHighest verified quarter-end share count
Quarters reported24Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Dexcom Inc in Q3 2020. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 400.93K shares. The latest verified filing showed: Bought 187.0% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 187.0% more+261.24K shares · 400.93K shares reported after the change
Filing context

Quarter-end price $67.35 · Estimated holding basis $74.27

Q1 2026
Sold 6.4% of the position−9.58K shares · 139.69K shares remained
Filing context

Quarter-end price $62.80 · Estimated holding basis $87.22

Q4 2025
Bought 23.9% more+28.77K shares · 149.26K shares reported after the change
Filing context

Quarter-end price $66.37 · Estimated holding basis $87.22

Q3 2025
Sold 52.5% of the position−133.32K shares · 120.50K shares remained
Filing context

Quarter-end price $67.29 · Estimated holding basis $92.20

Q2 2025
Bought 256.0% more+182.52K shares · 253.81K shares reported after the change
Filing context

Quarter-end price $87.29 · Estimated holding basis $92.20

Q1 2025
Sold 27.2% of the position−26.64K shares · 71.30K shares remained
Filing context

Quarter-end price $68.29 · Estimated holding basis $104.77

Portfolio importance

How important is Dexcom Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#153of 997 reported positions
Peak portfolio weight0.3%Q3 2023
Best historical rank#51Q4 2021
At peak importanceQ3 2023
DXCM
0.3%
Largest holding
5.5%
Cross-investor discovery

Who else owns Dexcom Inc?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
DXCM0.0% of reported portfolio
Explore Dexcom Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$84.682026-09-14

Market context only; not an investor transaction price.

Latest filing quarter-end price$67.35Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$74.27Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.